Briacell Therap (BCTX) Competitors $0.76 +0.02 (+3.11%) Closing price 04:00 PM EasternExtended Trading$0.76 -0.01 (-0.92%) As of 05:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCTX vs. PASG, PULM, ASBP, CMMB, DARE, IMNN, LSB, NRSN, SYBX, and LEXXShould you be buying Briacell Therap stock or one of its competitors? The main competitors of Briacell Therap include Passage Bio (PASG), Pulmatrix (PULM), Aspire Biopharma (ASBP), Chemomab Therapeutics (CMMB), Dare Bioscience (DARE), Imunon (IMNN), LakeShore Biopharma (LSB), NeuroSense Therapeutics (NRSN), Synlogic (SYBX), and Lexaria Bioscience (LEXX). These companies are all part of the "pharmaceutical products" industry. Briacell Therap vs. Its Competitors Passage Bio Pulmatrix Aspire Biopharma Chemomab Therapeutics Dare Bioscience Imunon LakeShore Biopharma NeuroSense Therapeutics Synlogic Lexaria Bioscience Briacell Therap (NASDAQ:BCTX) and Passage Bio (NASDAQ:PASG) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings. Do analysts recommend BCTX or PASG? Briacell Therap presently has a consensus target price of $32.00, indicating a potential upside of 4,093.97%. Passage Bio has a consensus target price of $91.75, indicating a potential upside of 1,170.78%. Given Briacell Therap's higher probable upside, equities analysts clearly believe Briacell Therap is more favorable than Passage Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Briacell Therap 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Passage Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders have more ownership in BCTX or PASG? 15.4% of Briacell Therap shares are owned by institutional investors. Comparatively, 53.5% of Passage Bio shares are owned by institutional investors. 5.7% of Briacell Therap shares are owned by insiders. Comparatively, 4.3% of Passage Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is BCTX or PASG more profitable? Passage Bio's return on equity of -103.87% beat Briacell Therap's return on equity.Company Net Margins Return on Equity Return on Assets Briacell TherapN/A -479.97% -182.26% Passage Bio N/A -103.87%-59.95% Which has more risk & volatility, BCTX or PASG? Briacell Therap has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500. Comparatively, Passage Bio has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500. Does the media favor BCTX or PASG? In the previous week, Passage Bio had 9 more articles in the media than Briacell Therap. MarketBeat recorded 16 mentions for Passage Bio and 7 mentions for Briacell Therap. Passage Bio's average media sentiment score of 0.65 beat Briacell Therap's score of 0.36 indicating that Passage Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Briacell Therap 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Passage Bio 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings & valuation, BCTX or PASG? Passage Bio is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBriacell TherapN/AN/A-$4.79M-$8.32-0.09Passage BioN/AN/A-$64.77M-$18.16-0.40 SummaryPassage Bio beats Briacell Therap on 7 of the 12 factors compared between the two stocks. Get Briacell Therap News Delivered to You Automatically Sign up to receive the latest news and ratings for BCTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCTX vs. The Competition Export to ExcelMetricBriacell TherapMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.17M$3.12B$5.70B$9.79BDividend YieldN/A2.21%3.77%4.10%P/E Ratio-0.0920.7930.8625.27Price / SalesN/A232.09403.8888.61Price / CashN/A41.5625.2228.45Price / Book-0.359.749.516.00Net Income-$4.79M-$54.74M$3.26B$265.34M7 Day Performance10.71%8.13%4.50%2.79%1 Month Performance-4.42%7.74%5.22%1.51%1 Year Performance-90.91%18.08%31.92%25.40% Briacell Therap Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCTXBriacell Therap2.8359 of 5 stars$0.76+3.1%$32.00+4,094.0%-91.2%$5.17MN/A-0.098Short Interest ↓PASGPassage Bio3.7715 of 5 stars$5.61-4.9%$150.00+2,573.8%-54.5%$18.41MN/A-0.28130Earnings ReportAnalyst RevisionGap UpPULMPulmatrix1.1881 of 5 stars$5.00flatN/A+132.0%$18.25M$369K-2.3020Short Interest ↓Gap UpASBPAspire BiopharmaN/A$0.36-1.6%N/AN/A$18.11MN/A0.00N/ANews CoverageEarnings ReportGap UpCMMBChemomab Therapeutics3.4558 of 5 stars$0.93-2.6%$8.50+818.9%-16.2%$17.91MN/A-1.2220Earnings ReportUpcoming EarningsShort Interest ↓Gap UpDAREDare Bioscience2.3549 of 5 stars$2.03+3.0%$12.00+491.1%-38.4%$17.79M$25.91K-11.9430Earnings ReportAnalyst UpgradeShort Interest ↓IMNNImunon1.5234 of 5 stars$6.84-3.4%$232.50+3,299.1%-62.6%$17.28M$500K-0.5330Gap UpLSBLakeShore Biopharma1.5057 of 5 stars$0.81+0.9%N/A-84.1%$16.67M$85.67M0.00773News CoveragePositive NewsUpcoming EarningsShort Interest ↓Gap UpNRSNNeuroSense Therapeutics2.5209 of 5 stars$1.12-6.7%$14.00+1,150.0%+54.5%$16.40MN/A-2.0710News CoverageAnalyst ForecastShort Interest ↑Gap DownSYBXSynlogic0.9571 of 5 stars$1.46+5.8%N/A+2.8%$16.15M$10K-0.5880Short Interest ↑High Trading VolumeLEXXLexaria Bioscience3.7814 of 5 stars$0.83+1.5%$4.00+379.9%-74.2%$16.07M$460K-1.247Short Interest ↓ Related Companies and Tools Related Companies PASG Alternatives PULM Alternatives ASBP Alternatives CMMB Alternatives DARE Alternatives IMNN Alternatives LSB Alternatives NRSN Alternatives SYBX Alternatives LEXX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCTX) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Briacell Therap Please log in to your account or sign up in order to add this asset to your watchlist. Share Briacell Therap With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access